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Abstract 
Prior research has demonstrated the reliability and validity of the Neurological 
Predictor Scale (NPS) in relation to childhood brain tumor survivor outcomes; however, 
its use has not been examined in adult long-term survivors. The current study examines 
the concurrent validity of the NPS with long-term intellectual and adaptive outcomes in 
adult survivors of childhood brain tumors relative to individual variables alone. A total of 
68 adult survivors of childhood brain tumors (M=24 years old, SD=4) almost 16 years 
post diagnosis (SD=6) completed intellectual evaluations using the Wechsler 
Abbreviated Scale of Intelligence (WASI). Survivors’ adaptive functioning skills were 
assessed via informant structured clinical interviews (SIB-R). NPS scores were 
computed from data acquired from medical records. The NPS was significantly 
associated with intellectual (R2=0.208, p< .05) and adaptive outcomes (R2= 0.30, p< 
.05) over and above individual risk factors. Approximately 18% of long-term survivors 
were identified as impaired in intellectual outcomes, and 29% were identified as 
impaired in adaptive functioning in everyday life skills. The NPS quantifies the 
cumulative effects of treatment and neurological sequelae experienced by both short 
and long-term survivors of childhood brain tumors. It is a useful and easy measure to 
employ in clinical research that focuses on quantifying the neurological risk factors 
associated with long-term intellectual and adaptive functioning outcomes in adult 
survivors of childhood brain tumors.   
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Cumulative Neurological Factors Associated with Long-term Outcomes in Adult 
Survivors of Childhood Brain Tumors  
 
Introduction 
Modern multifaceted treatment regimens for childhood brain tumors have 
resulted in improved five-year survival rates (Ries, 2004) and a growing number of long-
term survivors such that the majority of children diagnosed with brain tumors are now 
surviving into adulthood (Gurney et al., 2003). However, the risks for poor long-term 
outcomes are substantial, especially in those survivors treated aggressively and at a 
young age (Ellenberg et al., 2009; Mulhern, Merchant, Gajjar, Reddick, & Kun, 2004). 
Studies have documented lower or suboptimal intellectual and adaptive outcomes in 
pediatric brain tumor survivors compared to their healthy peers (Beebe et al., 2005; 
Papazoglou, King, Morris, & Krawiecki, 2008). Longitudinal studies have reported that 
these children are acquiring intellectual and adaptive skills at a slower rate relative to 
their same age peers but are not losing skills over time (Netson, Conklin, Wu, Xiong, & 
Merchant, 2013; Palmer et al., 2001). By the time individuals are reaching adulthood, 
there are increased demands on and expectations of rapid development of cognitive 
abilities and independent living skills, but young adult survivors may experience more 
significant impairments relative to peers who are gaining these skills. Poor adult 
outcomes and neurocognitive impairment have primarily been documented via survey-
based research by the Childhood Cancer Survivor Study (Ellenberg et al., 2009). 
Therefore, it is critical to better understand the neurological factors associated with long-
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term intellectual performance and adaptive outcomes in adult survivors of childhood 
brain tumors.  
The research literature on long-term outcomes in adult survivors of brain tumors 
has identified numerous treatment factors and health risks that are associated with poor 
outcomes. Of these, radiation therapy is the most commonly reported predictor of poor 
outcomes, and this finding has been supported through a number of studies using 
various methodologies (e.g., radiation type, location, dose, age at radiation, time since 
radiation:  (Armstrong et al., 2010; Armstrong et al., 2009; Mulhern, Hancock, 
Fairclough, & Kun, 1992). Often a proportion of participants are administered radiation 
concurrently with chemotherapy as together these treatments contribute to increased 
survival, albeit with negative cognitive and adaptive outcomes. In addition, other factors 
such as hydrocephalus, seizures, and endocrine dysfunction have also been shown to 
contribute to late effects described in survivors (Anderson, 2003; Ater et al., 1996; 
Bruininks, Woodcock, Weatherman, & Hill, 1996; Duffner, 2004, 2010; Hardy, Bonner, 
Willard, Watral, & Gururangan, 2008; King et al., 2004; Ris & Noll, 1994). These 
common neurological factors that influence outcomes are numerous, interactive and 
cumulative (Micklewright, King, Morris, & Krawiecki, 2008; Roman & Sperduto, 1995).  
In a field with traditionally more limited sample sizes (Mulhern, Carpentieri, 
Shema, Stone, & Fairclough, 1993; Ris & Noll, 1994), examining these potential 
confounding and interrelated variables is complex and challenging. Ideally, clinical 
research would be able to employ multivariate modeling approaches to address the 
interactions between these important factors. However, the examination of multivariate 
interactions requires a sizeable sample in order to have enough power to detect 
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significance, and smaller samples may present misleading results if interactions are not 
significant due to inadequate power and small effects. Similarly, in research designs 
when a large homogenous sample across each of these factors is not possible, 
examining the cumulative nature of the factors may help elucidate important 
contributions to outcomes. Although it is not as direct as examining multivariate 
interaction, it is important to consider not only the relation of each potential contributor 
to outcomes but also the cumulative neuro-oncology risk factors that are associated 
with the long-term outcomes of survivors of childhood brain tumors.  
The Neurological Predictor Scale (NPS) provides researchers the ability to 
quantify the cumulative effects of tumor and treatment-related conditions (Micklewright 
et al., 2008). This measure takes into account the multiple treatments or neurological 
sequelae which the individual may have experienced. Studies have documented the 
reliability and concurrent validity in childhood survivors (Micklewright et al., 2008; 
Papazoglou, King, Morris, & Krawiecki, 2009), but its concurrent validity has not yet 
been examined in adult survivors of childhood brain tumors. The current study aims to 
examine the concurrent validity of the NPS in adult survivors of childhood brain tumors.   
Methods 
Participants and Procedures 
 The study was reviewed and approved by the local institutional review boards, 
and all participants provided informed consent. Adult survivors were recruited through 
three different methods. First, adults who had been treated for a pediatric brain tumor at 
Children’s Healthcare of Atlanta were identified. Second, survivors who had previously 
been part of a childhood brain tumor study were identified. Based on these two lists, a 
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total of 676 letters were mailed; of these, 88 letters were returned due to an incorrect 
address. Finally, the Brain Tumor Foundation of Georgia ran an advertisement in their 
annual newsletter requesting participation in this study, which prompted other survivors 
to call to volunteer to participate in the study. Participants were excluded if English was 
not their first language, if they met criteria for pervasive developmental disorders, if they 
indicated a diagnosis of neurofibromatosis, or if they had experienced a traumatic brain 
injury (TBI).  Notably, the sample included one participant who had experienced a 
stroke and five individuals who experienced posterior fossa syndrome following surgery. 
As these complications may contribute important neurological information associated 
with long-term outcomes, we did not exclude these individuals from the sample. 
However, to ensure that these individuals were not solely contributing to the results, the 
statistical analyses were rerun without these six individuals, and the results did not 
appreciably change. Therefore, the results presented include survivors who have 
experienced posterior fossa syndrome, as well as one person who has had a stroke. All 
participants were over the age of 18 and were at least five years past their most recent 
diagnosis in order to assess the effects of long-term survivorship. 
Information about the brain tumor, subsequent treatments, and related 
neurological risk factors were obtained from a retrospective medical records review. We 
requested and reviewed physical medical records for all individuals who had been 
treated for their brain tumor before 2002 at Children’s Healthcare of Atlanta. All medical 
encounters after 2002 were reviewed through an electronic health record software. For 
each participant in our study, we obtained information regarding tumor type (based on 
histology lab reports), tumor location (based on notes from the surgeon who had 
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excised the tumor and MRI scan notes from radiologists) and all subsequent treatments 
(e.g. protocol numbers, type and dosage of radiation,  chemotherapy, medications, type 
of surgery and dates surrounding these treatments). We also gathered information 
about comorbid neurological factors such as seizures, types of seizure medications, 
presence and types of hormone deficiency, presence of hydrocephalus and ensuing 
treatments for hydrocephalus. Data extraction agreement was 98% between raters. All 
discrepancies were discussed between the raters and resolved before being single- and 
double- entered into a database. 
Overall, 68 participants were included in the analysis. The sample included 39 
females and 29 males. Participants in the sample were between 18 and 35 years old, 
with an average age of 23.78 years (SD = 4.43). Additionally, participants were an 
average of 15.8 years post diagnosis (SD = 6.13). Tumor locations and tumor types 
were heterogeneous. About half of the sample was diagnosed with either 
medulloblastomas (29%) or juvenile pilocytic astrocytomas (22%); the remainder of the 
sample was diagnosed with one of 15 different types of brain tumors (See Table I). 
Brain tumor locations were also varied; the most common location for brain tumors was 
the posterior fossa (62%), followed by the cerebral hemispheres (24%). For a complete 
list of the characteristics of the sample, including but not limited to brain tumor type, 
location, and treatment variables, refer to Table I.  
 
Measures 
 Wechsler Abbreviated Scale of Intelligence (WASI) 
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 The WASI is a nationally standardized abbreviated measure of intelligence 
comprised of four subtests. The measure has been shown to be reliable and valid, with 
high correlations with other established intelligence measures (Wechsler, 1999). 
Administration of all four subtests of this measure yields three indices: a verbal 
intelligence score (measuring expressive vocabulary, verbal knowledge and abstract 
verbal reasoning ability), a perceptual intelligence score (measuring spatial 
visualization, visual-motor coordination and nonverbal fluid reasoning), and an overall 
intellectual functioning score.  
 
 Scales of Independent Behavior - Revised (SIB-R) 
 The SIB-R is a norm-referenced assessment of adaptive and maladaptive 
behavior in school, home, employment, and community settings. Informants were 
interviewed by a trained graduate research assistant face-to-face. Informants were 82% 
parents, 9% spouse/partner, 3% grandparents/legal guardian, 3% siblings and 3% 
friends/roommates. Administration of this measure yields estimates of motor skills, 
social interaction/communication skills, personal living skills, community living skills, and 
broad independent living skills. These indices have demonstrated good reliability and 
validity in a number of populations (Bruininks et al., 1996). 
 
 Neurological Predictor Scale (NPS) 
The NPS is a brief measure that incorporates tumor, tumor treatment, and other 
related neurological risk factors into one score. Prior to completing the NPS, two 
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independent graduate students extracted information regarding treatments and 
commonly associated neurological risk factors from medical records.  
These conditions and treatments were further coded into a corresponding 
number based on the NPS.  As the items on the scale are objective ratings of 
treatments (i.e., presence or absence of treatments and conditions that are clearly and 
easily captured with a thorough medical records review) and subscores for each item on 
the scale are summed through a computer program, there was high agreement among 
raters (100%). The measure has been validated with a small sample of child survivors 
of childhood brain tumors (Micklewright et al., 2008), and the purpose of the present 
study is to examine the concurrent validity of the scale in a larger sample of adult 
survivors of childhood brain tumors.  
 
Data Analysis 
 First, we conducted a series of simple linear regression analyses. In these 
analyses, the NPS score was the independent variable, while intelligence measures 
(i.e., intellectual performance: verbal intelligence, perceptual intelligence) and adaptive 
functioning skill measures (i.e., broad independent living skills, motor skills, social 
communication skills, personal living skills and community living skills) were the 
dependent variables. This step was designed to ensure that the variance in NPS scores 
was significantly associated with the variance in the outcome measures in adult 
survivors of pediatric brain tumors.  
 Second, we conducted a series of hierarchical regression analyses to ascertain 
that the NPS score explains an additional amount of variance in two of the outcome 
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measures (i.e., intellectual ability as indicated by the WASI and broad independent 
living skills) above and beyond the variance already explained by any individual factor. 
Individual treatment- or illness-related factors examined included type of radiation (i.e., 
no radiation, focal, whole brain, and whole brain with focal boost), presence of 
chemotherapy, presence of neurosurgery, presence of hydrocephalus, presence of 
hormone deficiency, and presence of seizure medications. 
 
Results 
 A series of simple linear regression analyses indicated that the NPS scores were 
significantly associated with all of the dependent variables of interest. Specifically, the 
NPS scores were associated with intellectual performance, β = -0.46, t(66) = -4.16, p < 
.001, and 20.8% of the variance for intellectual ability (R2 = 0.208, F(1,66)=17.33, p < 
.01). The NPS scores also were also significantly associated with the participants’ 
verbal intelligence scores, β = -0.40, t(66) = -3.52, p <.001, and perceptual intelligence 
scores, β = -0.45, t(66) = -4.11, p < .001. The NPS scores were associated with 15.8% 
of the variance for verbal intelligence (R2 = 0.158, F(1,66)=12.42, p < .01) and 20.4% of 
the variance for perceptual intelligence scores (R2 = 0.204, F(1,66)=16.92, p < .01).  
 The NPS scores were significantly associated with broad independent living 
skills, β = -0.55, t(66) = -5.3, p < .001, and accounted for 30% of the variance in broad 
independent living skills (R2 = 0.30, F(1,66)=28.10, p < .001). The NPS scores were 
significantly associated with each of the component scores for adaptive functioning 
skills: motor ability (β = -0.55, t(66) = -5.3, p < .001), social communication skills (β = -
0.483, t(66) = -4.48, p < .001), personal living skills (β = -0.47, t(66) = -4.32, p < .001) 
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and community living skills (β = -0.49, t(66) = -4.60, p < .001). The NPS scores were 
also associated with between 22% and 36% of the variance of the SIB-R subscale 
scores (see Table II for specific values). In sum, the NPS was significantly associated 
with our dependent variables of interest: verbal intelligence, perceptual intelligence and 
adaptive functioning skills. 
 A series of hierarchical multiple regression analyses were conducted to evaluate 
whether the NPS scores accounted for a significant amount of variance above and 
beyond the contributions of individual treatment and illness-related variables (i.e., 
radiation, chemotherapy, neurosurgery, hydrocephalus, hormone deficiencies and 
seizure medications). The results indicated that the NPS scores accounted for a 
significant amount of the variance in overall intellectual functioning after controlling for 
the type of radiation (R2∆ = 0.076, p < 0.05), presence of chemotherapy (R2∆ = 0.137, p 
< .05), presence of neurosurgery (R2∆ = 0.222, p < .05), presence of hydrocephalus 
(R2∆ = 0.166, p < .05), presence of hormone deficiencies (R2∆ = 0.185, p < .05) and 
presence of seizure medications (R2∆ = 0.208, p < .05). Similarly, the NPS scores 
accounted for a significant amount of the variance in broad independent living skills 
after controlling for individually examined treatment- and illness-related variables, 
including type of radiation (R2∆ = 0.098, p < .05), presence of chemotherapy (R2∆ = 
0.161, p < .05), presence of neurosurgery (R2∆ = 0.309, p < .05), presence of 
hydrocephalus (R2∆ = 0.276, p < .05), presence of hormone deficiencies (R2∆ = 0.232, 
p < .05) and presence of seizure medications (R2∆ = 0.298, p < .05). Table III displays 
additional details regarding each step of the hierarchical regressions and the change in 
adjusted R2 associated with each step, as well as the standardized coefficients 
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associated with each independent variable in the models. These analyses show that 
NPS scores were associated with intellectual and adaptive outcomes above and beyond 
each individual treatment or neurological risk factor. 
 In order to capture the diverse nature of the impact of treatments and tumor 
sequelae on outcomes, the inclusion of a heterogeneous tumor group was important for 
this study. Patients with rare diagnoses or other complicating conditions (stroke, 
posterior fossa syndrome) were examined in order to ensure that these participants 
were not appreciably influencing the association that we found between NPS scores 
and our dependent variables of interest. Examination of the scatterplots ensured that 
none of these rare cases were outliers. After removing the rare tumor cases and 
patients with complicating conditions (stroke, posterior fossa syndrome) from the 
analyses, the strength and directionality of the results did not appreciably change. 
 
Discussion 
The present study demonstrates that the NPS is more associated with intellectual 
and adaptive outcomes of childhood brain tumor survivors on average over 15 years 
post diagnosis than each independently examined individual treatment or neurological 
risk factor. The proportion of variance that the NPS accounted for ranged from 16 to 
36% with medium-to-large effect sizes (0.4-0.6). These findings are consistent with past 
NPS studies on childhood brain tumor survivors (Micklewright et al., 2008; Papazoglou 
et al., 2009) suggesting that the NPS is a more robust measure of the complexity of 
neurological risk factors compared to one risk factor alone and that the NPS affords 
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studies great power in detecting the role of cumulative neurological factors in long-term 
cognitive and adaptive outcomes. 
 The current findings also are consistent with previous literature on treatments 
(chemotherapy, radiation, neurosurgery) and neurological sequelae (hydrocephalus, 
seizure, and endocrine) (Anderson, 2003; Armstrong et al., 2009; Ater et al., 1996; 
Bruininks et al., 1996; Duffner, 2004, 2010; Hardy et al., 2008; King et al., 2004; 
Mulhern et al., 1992; Ris & Noll, 1994; Roman & Sperduto, 1995) being strongly 
associated with survivor outcomes. However, the current study demonstrates that the 
NPS is better than any one factor alone, as it takes into account the complexity and 
cumulative nature of neurological complications that are related to long-term outcomes 
in childhood brain tumor survivors. 
Interestingly, survivors on average performed similar to peers on the WASI but a 
wide range of outcomes were evidenced. Indeed, 17.6% of the survivors were impaired 
on the intelligence measure (z ≤ -1.5). Similarly, adaptive outcomes were within normal 
limits on average but spanned an extremely wide range, and 29% of the sample was 
identified as impaired in the areas of adaptive functioning and day to day living skills on 
the SIB-R. The SIB-R is a structured clinical interview with informants who know the 
survivor well and observe him or her engaging in daily activities. This measure was 
even more robustly related to the NPS and identified a larger number of more 
significantly impaired survivors. This suggests that in spite of average intellectual 
performance, a sizeable proportion (29%) of survivors is impaired in terms of everyday 
life skills. Furthermore, as neurological complications increase, it is more likely that 
impaired ability will be found in everyday function, which increases dependence on 
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others. These findings are particularly important with young adult survivors whose peers 
are completing college or advanced education, securing employment or careers, 
developing and maintaining friendships and partners, and negotiating leisure activities in 
the community.  
A greater proportion of impaired adaptive living skills may be related to another 
variable or variables, such as one or more impaired core cognitive skills. Disruption of 
core cognitive skills such as processing speed, attention, and/or working memory are 
commonly reported in the literature (Palmer, 2008; Reddick et al., 2003; Wolfe, Madan-
Swain, & Kana, 2012) and may be better captured by the adaptive functioning skills in 
the SIB-R compared to the WASI. We specifically selected the WASI for the IQ measure 
so that these core cognitive skills would be less likely to depress estimates of global 
cognitive ability. Therefore the possibility of the NPS demonstrating concurrent validity 
with core cognitive skills should be examined in the future. In addition, these findings 
further support the benefit of obtaining complementary information about survivorship 
outcomes with both cognitive performance and informant report of everyday abilities.  
It is important to note that treatment intensity has been examined to some extent 
in existing research literature. In these studies, the intensity variable is generally defined 
(in order from least to most intense) as stepwise groups of siblings, patients with acute 
lymphoblastic leukemia (ALL), patients with typical radiation with or without 
chemotherapy, and patients with a higher level of radiation with or without 
chemotherapy. However, modeling and measuring treatment intensity in this manner 
may not always be appropriate. Depending on the specific research question, how one 
quantifies treatment intensity or risk/prognostic factors is important. One could argue 
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that a cumulative scale that takes into account factors common to brain tumor patients 
is superior to comparing across disease (e.g., ALL, brain tumor, and other cancer). For 
example, brain tumor patients share some extent of neurosurgery (subtotal, gross total, 
biopsy), hydrocephalus, or seizure medication. However, when comparing a radiation 
group to a no radiation group, participants may also differ on whether they received 
chemotherapy or if they had neuroendocrine involvement. Simply reporting that the 
findings are due to the neurotoxic effects of radiation may be misleading. 
Acknowledging co-occurring factors and potential confounds as well as quantifying the 
cumulative nature of these differences as the NPS scores do may advance research in 
the field.   
The NPS may be used as a tool for further examining research findings and 
parsing apart how treatment complexities relate to main research findings. For example, 
across radiation and no-radiation groups, one may examine how NPS scores or 
increased cumulative neurological risk are related to later reduced adaptive functioning 
(Papazoglou et al., 2009). The initial paper on the NPS (Micklewright et al., 2008) 
demonstrated concurrent validity in 25 short-term childhood brain tumor survivors with 
the NPS and IQ. Our research team also demonstrated that the NPS and parent report 
of attention problems was associated with later adaptive functioning in 42 children 
treated for brain tumors (Papazoglou et al., 2009). Another research team has recently 
demonstrated concurrent validity in an independent sample of 82 childhood brain tumor 
survivors on average 2.4 years since treatment, with the NPS and intellectual outcome 
(McCurdy, Rane, Daly, Jacobson, 2014). Similarly, another study examined an 
independent sample of 75 childhood brain tumor survivors on average 2.5 years since 
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treatment, and found that poorer processing speed and working memory outcomes 
were associated with the NPS (McCurdy, 2014). In addition, our research team recently 
demonstrated that the NPS was specifically related to hippocampal and putamen 
volume but not associated with whole brain volume in 35 adult survivors of childhood 
brain tumors (Jayakar, King, Morris, & Na, 2015). NPS findings such as these help to 
promote ideas for future larger scale research studies and expand the focus of research 
beyond radiation treatment alone. Although radiation treatment is a critical factor in 
outcome research, it may be misleading if complementary analyses of neurological 
complexity are not also considered. Therefore, the NPS appears to be associated with 
outcomes across different types of measurement without shared method variance, 
suggesting strong concurrent validity in both child and adult survivors of childhood brain 
tumors.  
 The current study should be considered in the context of its limitations. 
Participants were recruited through different mechanisms (e.g., letters and newsletters) 
making it difficult to know the true source population. Therefore, there may be selection 
bias in those participants who contacted the research team to participate in the study. It 
may be that the survivors who wanted to participate were more impaired and wanted 
more health care provider contact. It is equally possible, in this convenience sample, 
that the survivors who wanted to participate were more able to given higher cognitive or 
adaptive functioning skills.  Another limitation that should be considered is that the 
survivors in this study were treated between 1979 and 2008 and therefore are unlikely 
to reflect the most recent treatment advances being implemented. That said, the 
growing number of survivors requires multidisciplinary teams in order to continue 
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considering the role of these cumulative risk factors from older treatment practices in 
long-term outcomes. It also is recognized that some study designs may have a precise 
question about the role of radiation dosages to specific brain areas in specific diagnostic 
groups. In this situation, highly homogenous diagnostic and radiation treatment data is 
necessary. However, to rule out other potential confounds that may be concurrently 
contributing to the outcomes observed in that hypothetical homogenous group, 
researchers may consider using the NPS to quantify other complex medical factors that 
may differ between participants and identify how much additional variance these related 
factors may also contribute. While the NPS is not able to contribute to specific 
hypotheses that require a refined measurement strategy such as dosimetry or integral 
biologically effective dose (IBED:(Ris, 2007) when examining the impact of radiation on 
cognitive outcome, it may provide complementary information in the same study about 
the association between the cumulative risk and outcomes, indicating the other 
potentially important co-occurring complications. Therefore, the NPS has the potential to 
contribute to our knowledge of complex risk factors in survivors of childhood brain 
tumors. Future prospective longitudinal studies with larger samples may consider 
exploring if the cumulative NPS scale adds complementary information to multivariate 
analyses.   
In any location in the world, the sample size of children undergoing treatment for 
brain tumor is fortunately not large. In order to capture the multiple potential 
complications a survivor may experience, a cumulative measure such as the NPS may 
be the easiest to implement. The NPS as it is currently designed is not able to examine 
the interactions that may exist between individual treatment factors, but it is certainly a 
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first step toward examining neurological complexity within brain tumor samples above 
and beyond simple descriptive reports of each variable. 
In summary, the current study demonstrates the concurrent validity between the 
NPS and intellectual and adaptive functioning measures. Based on these results, the 
NPS may be an informative clinical research tool especially in studies with 
heterogeneous brain tumor samples. Notably, the NPS is very user-friendly; the scale is 
clear, straightforward and efficient to complete after obtaining thorough medical record 
review information. Future research could examine the role of these factors when 
examining neurobiological variables (e.g., white matter volume and microstructure), 
core cognitive (e.g., processing speed, attention and working memory) and 
psychosocial outcomes, quality of life, and other factors critical to improving long-term 
cancer survivorship. 
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Table I. Demographic, Diagnostic and Treatment Variables. 
Variables Survivors (n=68) 
Demographic Variables  
Female (n, %) 39 (57%) 
Hollingshead socio-economic status (mean ± SD) 2.2 ± 1.09 
Age at testing (mean ± SD) 23.78 ± 4.43 
   Range 18-35 
Ethnicity (n, %)  
   Caucasian 55 (81%) 
   African-American 9 (13%) 
   Other 4 (6%) 
Employment status (n, %)  
   Student 31 (46%) 
   Employed 22 (32%) 
   Unemployed 8 (12%) 
   Disability 7 (10%) 
Diagnostic Variables  
Years post diagnosis (mean ± SD) 
 Range 
15.8 ± 6.13 
5 – 28 
Age at diagnosis (mean ± SD) 
 Range 
7.96 ± 4.8 
0 – 17 
Tumor location (n, %) 
 
   Posterior fossa 42 (62%) 
   Cerebral hemispheres 16 (24%) 
   Ventricles 5 (7%) 
   Pituitary 3 (4%) 
   Brain stem 2 (3%) 
Tumor type (n, %) 
 
   Medulloblastoma 20 (29%) 
   Juvenile pilocytic astrocytoma 15 (22%) 
   Diffuse astrocytoma 6 (9%) 
   Craniopharyngioma 5 (7%) 
   Ganglioglioma 3 (4%) 
   Ependymoma 3 (4%) 
   Other†  16 (25%) 
Treatment Variables  
Radiation (n, %) 35 (52%) 
Radiation type (n, %)  
   Focal 8 (23%) 
   Whole brain 4 (11%) 
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   Craniospinal with boost 23 (66%) 
Chemotherapy (n, %) 25 (37%) 
Neurosurgery 67 (99%) 
Hydrocephalus (n, %) 46 (68%) 
Seizure Medication (n, %) 18 (27%) 
Hormone deficiency (n, %) 33 (49%) 
Hormone deficiency type (n, %)  
   Hypothyroidism 22 (32%) 
   Growth hormone deficiency 15 (22%) 
   Hypogonadism 6 (9%) 
   Hypoadrenalism 5 (7%) 
Measures  
   Full scale IQ (mean ± SD) 
 Range 
            % impaired (≤-1.5z) 
95.53 ± 18.79 
54 – 128 
17.6 % 
   Broad independent living skills standard score 
            (mean ± SD) 
 Range 
            % impaired (≤-1.5z) 
 
95.24 ± 28.98 
33 – 144 
29.4 % 
Note. †Two oligodendroglioma, two brainstem glioma, two anaplastic astrocytoma, two 
cerebral neuroblastoma, two mixed astrocytoma/ganglioglioma, one malignant 
melanoma, one pineoblastoma, one meningioma, one germ cell tumor, one 
medulloepithelioma, one non-infiltrative mesenchymal neoplasm, not otherwise 
specified. 
 
Table II. Simple Linear Regression Models of the Predictive Relationship Between NPS 
and Various Dependent Variables of Interest (n=68) 
 
Measure 
 
B 
 
SE B 
 
β 
 
t 
 
p 
Full Scale IQ -3.81 0.92 -.46 -4.16 <.001** 
   Verbal IQ -3.08 0.87 -.40 -3.52   .001** 
   Perceptual IQ -3.76 0.91 -.45 -4.11 <.001** 
Broad Independent Living 
Skills 
-7.04 1.33 -.55 -5.30 <.001** 
   Motor Skills -8.85 1.44 -.60 -6.15 <.001** 
   Social Communication Skills -4.93 1.10 -.48 -4.48 <.001** 
   Personal Living Skills -4.69 1.09 -.47 -4.32 <.001** 
   Community Living Skills -5.42 1.18 -.49 -4.60 <.001** 
Note. *p < .05, ** p < .01 
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Table III Hierarchical Regression Models Relating Intelligence and Broad Independent 
Living Skills to Treatment Related Factors and NPS Scores (N=68) 
 
Intellectual Functioning Broad Independent Living 
Skills 
 
Individual Treatment Factor 
 
Adjusted 
R2 
 
∆ R2 
 
β 
 
Adjusted 
R2 
 
∆ R2 
 
β 
Radiation       
   Model 1 .12 .13  .18 .19  
      Type of Radiation   -.36**   -.44** 
   Model 2 .18 .08  .27 .10  
      Type of Radiation   .07   .05 
      NPS Score   -.51*   -.58** 
Chemotherapy       
   Model 1 .07 .08  .13 .14  
      Presence of Chemotherapy   -.29*   -.38** 
   Model 2 .20 .14  .28 .16  
      Presence of Chemotherapy   .18   .12 
      NPS Score   -
.593** 
  -.64** 
Neurosurgery       
   Model 1 -.02 .0  -.015 .0  
      Presence of Neurosurgery   .017   -.02 
   Model 2 .20 .22  .29 .31  
      Presence of Neurosurgery   .12   .11 
      NPS Score   -.48**   -.57** 
Hydrocephalus       
   Model 1 .04 .05  .01 .02  
      Presence of Hydrocephalus   -.23   -.15 
   Model 2 .20 .17  .28 .28  
      Presence of Hydrocephalus   -.11   .002 
      NPS Score    -.42**   -.55** 
Hormone Deficiencies       
   Model 1 -.003 .012 -.114 .10 .11  
      Presence of Hormone Deficiencies      -.34** 
   Model 2 .22 .23  .28 .19  
      Presence of Hormone Deficiencies   .23   -.04 
      NPS Score   -.59**   -.53** 
Seizure Medication       
   Model 1 .0 -.02  -.02 .0  
      Presence of Seizure Medications   -.017   -.02 
   Model 2 .18 .21  .28 .30  
      Presence of Seizure Medications   -.006   -.007 
      NPS Score   -.46**   -.55** 
Note. *p < .05, ** p < .01  All beta values for NPS scores in the second models for both dependent variables were significant. This 
finding indicates that NPS continues to predict intellectual and adaptive outcomes after controlling for individual risk factors. 
